Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
France Targets Shein, Temu With Fast-Fashion Fees 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
NEW HAVEN, Conn., March 08, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15 a.m. ET at the Loews Miami Beach Hotel in Miami, FL.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to bring life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
